Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Levetiracetam in Subarachnoid Hemorrhage
Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Levetiracetam in Subarachnoid Hemorrhage
This study evaluates the pharmacokinetic profile of levetiracetam in critically ill patients
 who have suffered a subarachnoid hemorrhage. The patients will be evaluated for development
 of augmented renal clearance and the effects and duration of effects this may have on
 levetiracetam clearance.
Inclusion Criteria:

 -  Patients diagnosed with non-traumatic subarachnoid hemorrhage requiring levetiracetam
 for seizure prophylaxis or treatment

 -  Presentation to University of Colorado Hospital within 48 hours of subarachnoid
 hemorrhage

 -  Adults ages 18 to 89 years

 -  Anticipated length of stay ≥ 48 hours

 -  Informed consent provided by the patient or patient's designated medical proxy

 Exclusion Criteria:

 -  Pregnancy

 -  Patients receiving renal replacement therapy

 -  Brain death or imminent brain death expected ≤48 hours

 -  Patient with history of nephrectomy or renal transplant